Keyphrases
C-Met
100%
Targeted Therapy
100%
Osteosarcoma
100%
Dual Aptamer
100%
PROTAC Degraders
100%
Proteolysis Targeting chimera (PROTAC)
85%
AS1411
85%
Nucleolin
42%
Linker
28%
Aptamer
28%
Tumor Targeting
28%
Murine Double Minute 2 (MDM2)
28%
Nucleic Acids
28%
Chimera
28%
Single-stranded DNA (ssDNA)
14%
Apoptosis
14%
Tumor Cells
14%
Therapeutic Efficacy
14%
Ubiquitination
14%
Tumor
14%
Safety Concerns
14%
In Vivo Experiment
14%
Therapeutic Target
14%
Drug Resistance
14%
E3 Ligase
14%
Recruiters
14%
Acquired Resistance
14%
Repurposing
14%
Degrader
14%
Antitumor Efficacy
14%
Osteosarcoma Treatment
14%
Osteosarcoma Cells
14%
Drug Resistance Reversal
14%
In Vivo Tumor Targeting
14%
Bone Malignancy
14%
MET Inhibitor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Aptamer
100%
Osteosarcoma
100%
Neoplasm
80%
Nucleolin
60%
Drug Resistance
40%
Nucleic Acid
40%
Combination Therapy
20%
Side Effect
20%
Base
20%
Ligase
20%
Biochemistry, Genetics and Molecular Biology
Aptamer
100%
Nucleolin
75%
Drug Resistance
50%
Nucleic Acid
50%
Programmed Cell Death
25%
Ubiquitination
25%
Ubiquitin Ligase
25%
Immunology and Microbiology
Drug Resistance
100%
Programmed Cell Death
50%
Tumor Cell
50%
Ubiquitination
50%
Osteosarcoma Cell
50%
Material Science
Tumor
100%
Nucleic Acid
50%
Surface (Surface Science)
25%
Ubiquitylation
25%
Chemistry
Proteolysis Targeting Chimera
100%
Nucleic Acid
28%
Antitumor
14%
Pair-Base
14%
Ubiquitylation
14%